These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 15116055

  • 21. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.
    Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR, Alloway RR, Meibohm B.
    J Clin Pharmacol; 2003 Jun; 43(6):555-64. PubMed ID: 12817518
    [Abstract] [Full Text] [Related]

  • 22. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T.
    Transplantation; 2004 Oct 27; 78(8):1182-7. PubMed ID: 15502717
    [Abstract] [Full Text] [Related]

  • 23. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients.
    Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O.
    Transplantation; 2008 Nov 15; 86(9):1206-13. PubMed ID: 19005401
    [Abstract] [Full Text] [Related]

  • 24. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects.
    Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL.
    Clin Pharmacol Ther; 2003 Nov 15; 74(5):487-98. PubMed ID: 14586389
    [Abstract] [Full Text] [Related]

  • 25. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.
    Basic Clin Pharmacol Toxicol; 2008 Dec 15; 103(6):546-52. PubMed ID: 19067682
    [Abstract] [Full Text] [Related]

  • 26. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C, Everolimus Phase 2 Study Group.
    Clin Pharmacol Ther; 2001 Jan 15; 69(1):48-56. PubMed ID: 11180038
    [Abstract] [Full Text] [Related]

  • 27. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements.
    Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW, MacPhee IA.
    Transplantation; 2006 Sep 15; 82(5):705-8. PubMed ID: 16969296
    [Abstract] [Full Text] [Related]

  • 28. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
    Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, Brunet C, Gastaut JA, Durand A, Lacarelle B, Poizot-Martin I.
    Br J Clin Pharmacol; 2007 Sep 15; 64(3):353-62. PubMed ID: 17517050
    [Abstract] [Full Text] [Related]

  • 29. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J, Kim MG, Choi B, Han NY, Yun HY, Yoon JH, Oh JM.
    Ann Pharmacother; 2012 Sep 15; 46(9):1141-51. PubMed ID: 22947591
    [Abstract] [Full Text] [Related]

  • 30. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
    Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK.
    Eur J Clin Pharmacol; 2008 Nov 15; 64(11):1069-84. PubMed ID: 18636247
    [Abstract] [Full Text] [Related]

  • 31. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem.
    Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X, Bi H, Huang M.
    Eur J Clin Pharmacol; 2009 Mar 15; 65(3):239-47. PubMed ID: 18936931
    [Abstract] [Full Text] [Related]

  • 32. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.
    Cai J, Huang Z, Yang G, Cheng K, Ye Q, Ming Y, Zuo X, Zhou P, Yuan H.
    Am J Cardiovasc Drugs; 2011 Dec 01; 11(6):401-9. PubMed ID: 22149319
    [Abstract] [Full Text] [Related]

  • 33. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.
    Zhu HJ, Yuan SH, Fang Y, Sun XZ, Kong H, Ge WH.
    Pharmacogenomics J; 2011 Jun 01; 11(3):237-46. PubMed ID: 20368718
    [Abstract] [Full Text] [Related]

  • 34. P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth.
    Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, Grabarek J.
    J Clin Periodontol; 2004 Sep 01; 31(9):758-63. PubMed ID: 15312098
    [Abstract] [Full Text] [Related]

  • 35. MDR1 C3435T polymorphism in patients with breast cancer.
    Turgut S, Yaren A, Kursunluoglu R, Turgut G.
    Arch Med Res; 2007 Jul 01; 38(5):539-44. PubMed ID: 17560460
    [Abstract] [Full Text] [Related]

  • 36. The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.
    Shilbayeh S, Zmeili R, Almardini RI.
    Saudi J Kidney Dis Transpl; 2013 Nov 01; 24(6):1125-36. PubMed ID: 24231473
    [Abstract] [Full Text] [Related]

  • 37. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T.
    Clin Pharmacol Ther; 2003 Sep 01; 74(3):245-54. PubMed ID: 12966368
    [Abstract] [Full Text] [Related]

  • 38. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
    Jordán de Luna C, Herrero Cervera MJ, Sánchez Lázaro I, Almenar Bonet L, Poveda Andrés JL, Aliño Pellicer SF.
    Transplant Proc; 2011 Sep 01; 43(6):2241-3. PubMed ID: 21839244
    [Abstract] [Full Text] [Related]

  • 39. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ.
    Ther Drug Monit; 2009 Apr 01; 31(2):187-97. PubMed ID: 19258929
    [Abstract] [Full Text] [Related]

  • 40. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G.
    Pharmacogenomics; 2011 Sep 01; 12(9):1293-303. PubMed ID: 21806386
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.